Fareva has completed an investment in high potency drug product manufacturing. The investment strengthens the group’s capabilities in high potency drugs to answer increasing market demand, it says. In the last several years, the company says, oncology drugs have represented more than 50% of the new chemical entities (NCE’s).
The program started in 2016 at the site of Fareva La Vallée, France. Increasing capacity for highly potent APIs was added, with a pilot plant, a production building and additional R&D laboratories.
In 2018-2019, Fareva’s Excella site in Germany also expanded its analytical capabilities and added roller compaction for highly potent drug product.
In April 2021, the group completed the acquisition of a Novartis’ site in Austria. The site specialises in injectable, high potency drug products, with packaging available in vials and pre-filled syringes.
Fareva Excella is continuing its expansion on high potency tablets and capsules operations with an investment of €25 m, which will is aimed to be available for production in 2023. The production facilities will be expanded this year with a 2,850 sqm building, designed to reach 500 million units per year capacity for tablets or capsules, up to OEB6 containment level. An additional suite for future demand is also a part of the program. Fareva Excella has numerous regulatory body approvals including FDA and PMDA certifications, it says.
